Product photograph of the current pack. Each physical unit carries the same blue-teal ZX label artwork, a batch code and a scratch-off verification panel.
BPC 157
Body Protective Compound 157
- Compound
- Body Protective Compound 157
- Category
- Peptides
- Brand
- BPC 157
- Manufacturer
- Zyvex Pharmaceuticals
- Presentation
- vial
- Strength
- 5 mg
- Route
- Injection
- Storage
- 15–25 °C, protected from light, do not freeze
Batch analysis
Independent batch results for BPC 157 are not yet published. They will be added here once testing is complete.
Product information
About BPC 157
5 mg · one vial · Zyvex Pharmaceuticals
BPC 157 from Zyvex Pharmaceuticals contains 5 mg of BPC-157 in one vial. The vial amount describes total content, not an administered dose.
This prospect summarises composition, clinical considerations and handling. It supports professional review and does not replace an individual prescription or verified instructions for the exact preparation.
Basic Identification & Composition
Product Name & Active Ingredient
BPC 157 is the product name used by Zyvex Pharmaceuticals. The ingredient discussed in the following sections is BPC-157, classified as a experimental peptide.
Qualitative & Quantitative Composition
| Property | Details |
|---|---|
| Product name | BPC 157 |
| Manufacturer | Zyvex Pharmaceuticals |
| Active ingredient | Body Protective Compound 157 |
| Strength | 5 mg |
| Package | one vial |
| Drug class | Experimental peptide |
| Chemical formula | C62H98N16O22 (peptide) |
| Presentation | Vial; preparation and route require formulation-specific instructions |
Dosage Form
A vial presentation. A vial may contain a ready-to-use preparation or material requiring preparation, so the exact dosage form must be confirmed before administration. Total milligrams do not establish concentration, injection volume or sterility.
Clinical Particulars
BPC 157 uses
BPC 157 from Zyvex Pharmaceuticals contains body protective compound 157. BPC-157 is investigated for tissue repair and related biological effects. A small retrospective clinical report examined knee pain after intra-articular treatment; that design cannot establish efficacy or a general treatment protocol.
People seek BPC-157 for tendon or joint symptoms, injury recovery and return to training. These intended uses should not be confused with demonstrated healing of a specific injury.
A dependable human dose, route and treatment duration for general injury recovery cannot be established from the reviewed evidence. The 5 mg vial is total content, not a treatment dose. Animal dosing and a joint-injection report cannot be converted into a home-injection schedule.
Dosage and Administration
A reliable routine human dosing regimen cannot be established from the available clinical evidence. The product strength must not be converted into a self-treatment schedule. Human use requires an appropriately supervised clinical or research setting with a defined protocol. The 5 mg vial content is not a recommended injection dose. Reconstitution, route and frequency should not be inferred from the vial size.
Contraindications
A complete clinical contraindication profile has not been established. Avoid exposure with known hypersensitivity, during pregnancy or breastfeeding, and in children outside a properly reviewed clinical setting. Absence of a listed contraindication is not evidence of safety.
Warnings and Precautions
BPC-157 has limited human safety evidence. Peptide impurities and immune reactions are concerns, particularly when injected. Laboratory or animal findings do not establish a safe treatment for injury or recovery. Fever, increasing redness or pain after an injection requires assessment.
Risks and Interactions
Drug & Food Interactions
Human interaction studies are limited. A clinician or study team should review all prescription medicines, nonprescription products and supplements. There is no basis for assuming that combinations with other experimental compounds are safe.
Pregnancy and Lactation
Adequate pregnancy, lactation and reproductive safety evidence is lacking. Avoid exposure during pregnancy or breastfeeding. Any reproductive-risk precautions in a clinical study should be directed by the study team.
Side Effects and Adverse Reactions
A dependable frequency-based adverse-reaction profile cannot be established from the available human evidence. Limited reports cannot rule out uncommon or delayed harm. Seek urgent care for breathing difficulty, facial swelling, collapse or severe symptoms after exposure.
Overdose Protocol
For a suspected overdose, contact a poison-information service or urgent medical care and provide the product, amount, time and other substances taken. Collapse, seizures or breathing difficulty require emergency help. Do not induce vomiting or attempt an antidote at home. Clinical treatment depends on symptoms and the substances involved.
Scientific & Technical Data
Pharmacodynamics
BPC-157 is a synthetic 15-amino-acid peptide investigated in experimental tissue-repair models. Proposed biological effects remain under study; there is no single clinically validated mechanism that supports a general healing claim.
Pharmacokinetics
Reliable human absorption, distribution, metabolism and excretion data for this vial formulation are not established. Animal or laboratory half-life estimates should not be used to set a human injection interval.
Storage and Handling
Keep the sealed container protected from direct light, excessive heat and accidental access. Temperature, transport conditions and expiry must be supported by stability information for the finished preparation. For a vial, any conditions after opening or preparation must also be validated for that formulation. Refrigeration alone does not establish sterility or a safe period of use. Arrange disposal through a pharmacist or the supervising research service.
Browse more